REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific antibody RC148 has demonstrated promising results in Phase I/II clinical trials for first-line monotherapy and second-line combination therapy in non-small cell lung cancer (NSCLC). Data revealed that RC148 exhibited significant clinical efficacy and manageable safety in both monotherapy and combination approaches, marking a dual-path breakthrough.

Based on early data from the RC148-C001 study, RC148, in combination with docetaxel, received Breakthrough Therapy Designation (BTD) in China in August 2025 for treating driver gene-negative locally advanced or metastatic NSCLC patients who failed prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy (sequential or concurrent). The company is actively advancing related clinical trials: according to investor updates, patient enrollment for the Phase II trial of RC148 combination therapy in first-line NSCLC has been completed, with plans to initiate a Phase III study. Institutions remain optimistic about its future clinical potential.